Leerink Downgrades Bristol Myers Squibb, FDA Expands Pediatric Label for Camzyos

Bristol Myers Squibb (NYSE: BMY) shares slid on October 5, 2026, following a downgrade by Leerink Partners, which lowered its rating from “Outperform” to “Market Perform” and cut its price target to $59, citing growing skepticism around the company’s drug development pipeline. As of October 5, 2026, the stock price stood at $58.81, reflecting a 1.8% intraday decline.

On the regulatory front, the FDA has granted an expanded indication for BMS’s heart-related therapy Camzyos (mavacamten), now approving it for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) weighing at least 30 kg. This marks the first FDA-approved therapeutic option for this younger population.

Leerink Downgrade Reflects Concerns Over Pipeline Visibility

On October 5, Leerink Partners downgraded BMY to Market Perform, citing doubts about the visibility and strength of the company’s upcoming clinical readouts. The slide in shares came as the firm reduced its price target significantly, from $73 to $59, emphasizing potential risks ahead in the development pipeline. This adjustment likely contributed to the observed dip in stock price.

FDA Expands Camzyos Label to Pediatric Patients

On September 30, the U.S. Food and Drug Administration approved an expanded indication for Camzyos, allowing its use in pediatric patients weighing 30 kg or more with symptomatic oHCM. Previously, the drug was approved in 2022 for adult patients with New York Heart Association class II–III oHCM to improve functional capacity and symptoms. With this new pediatric label, Camzyos becomes the only FDA-approved therapy available for treating oHCM in children, addressing a significant unmet need in cardiovascular care.

Why This Matters

The downgrade underscores lingering investor concerns about Bristol Myers Squibb’s ability to deliver on its late-stage pipeline, particularly amid a competitive biotech landscape. In contrast, the regulatory milestone for Camzyos could enhance the company’s profile in pediatric cardiology and support long-term growth in a niche but vital market segment.

Investors will likely monitor upcoming clinical readouts and further regulatory milestones closely, as these will influence sentiment and potentially inform future analyst outlooks.

Key Dates

• September 30, 2026: FDA approval for Camzyos expanded to pediatric patients.
• October 5, 2026: Leerink Partners downgraded BMY from Outperform to Market Perform.

With these developments, the balance between regulatory progress and pipeline skepticism shapes Bristol Myers Squibb’s near-term stock narrative. Upcoming earnings on October 29, 2026, may offer further clarity around company performance and forward guidance.